---
title: "Major Insider Move Signals Growing Confidence in Prothena Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296664234.md"
description: "On August 21, 2026, Prothena shareholder William Scully acquired 50,000 shares worth $439,000, signaling confidence in the biopharmaceutical firm. This move follows Q2 results with revenue above consensus and updates on partnered neurodegenerative disease programs. Despite positive insider activity and pipeline prospects, TipRanks' AI Analyst rates PRTA as Neutral due to weak financial performance, including declining revenue and cash burn, alongside a neutral-to-weak technical sentiment."
datetime: "2026-08-22T02:09:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296664234.md)
  - [en](https://longbridge.com/en/news/296664234.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296664234.md)
generator: "portal-rs"
---

# Major Insider Move Signals Growing Confidence in Prothena Shares

New insider activity at Prothena ( (PRTA) ) has taken place on August 21, 2026.

Significant shareholder William Scully has boosted his stake in Prothena by acquiring 50,000 shares of the company’s stock in a recent transaction, with the purchase valued at $439,000, signaling a notable vote of confidence in the biopharmaceutical firm.

Prothena’s stock reacted to Q2 results showing revenue above consensus and to updates across its partnered pipeline in neurodegenerative and amyloid diseases. Investor focus centered on the long-term value of Phase 2/3 programs with Roche, Novo Nordisk, and Bristol Myers Squibb, and on the prospect of sizable future milestones and royalties that support a more favorable longer-term outlook despite distant trial completions.

**Spark’s Take on PRTA Stock**

According to Spark, TipRanks’ AI Analyst, PRTA is a Neutral.

The score is primarily weighed down by weak financial performance—declining revenue, very large losses, and ongoing cash burn—partly offset by a strong, low-debt balance sheet. Technicals are neutral-to-weak with negative momentum and price below key long-term averages, while valuation support is limited given the negative P/E and no dividend. Corporate governance news is mildly positive but not a major fundamental driver.

To see Spark’s full report on PRTA stock,  
 click here. 

**More about Prothena**

**YTD Price Performance:** -5.45%

**Average Trading Volume:** 547,714

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $476.9M

### Related Stocks

- [PRTA.US](https://longbridge.com/en/quote/PRTA.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Prothena files initial beneficial ownership statement for Todd W. Fennell](https://longbridge.com/en/news/296266092.md)
- [Prothena 10% owner William P. Scully buys $439,430 of common shares](https://longbridge.com/en/news/296644095.md)
- [Prothena 10% owner William P. Scully buys $293,052 of common shares](https://longbridge.com/en/news/295440858.md)
- [Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/296585791.md)
- [Prothena files initial beneficial ownership statement for Todd W. Fennell](https://longbridge.com/en/news/295545699.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**